Zacks Research Expects Stronger Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Zacks Research increased their Q4 2024 earnings per share (EPS) estimates for shares of Zimmer Biomet in a report issued on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.29 per share for the quarter, up from their previous forecast of $2.26. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.13 EPS and Q1 2026 earnings at $2.28 EPS.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the firm posted $1.65 earnings per share.

A number of other analysts also recently weighed in on ZBH. Wells Fargo & Company increased their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Canaccord Genuity Group lowered their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 10th. Evercore ISI cut their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. UBS Group lowered their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research note on Thursday, August 8th. Finally, Truist Financial boosted their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $110.64 on Monday. The firm has a market cap of $22.03 billion, a P/E ratio of 21.03, a P/E/G ratio of 2.03 and a beta of 1.02. The stock’s 50 day moving average is $106.95 and its 200 day moving average is $109.47. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet has a one year low of $101.47 and a one year high of $133.90.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dunhill Financial LLC boosted its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new stake in Zimmer Biomet during the third quarter valued at about $28,000. Bangor Savings Bank purchased a new position in Zimmer Biomet in the 3rd quarter worth approximately $31,000. Family Firm Inc. purchased a new stake in Zimmer Biomet during the 2nd quarter valued at $33,000. Finally, Brooklyn Investment Group purchased a new stake in Zimmer Biomet in the 3rd quarter worth approximately $35,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.